Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2011 Jan;32(2):148-57.
doi: 10.1093/eurheartj/ehq427. Epub 2010 Nov 12.

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study

Thierry Lefèvre  1 , Ari Pieter Kappetein, Ernst Wolner, Patrick Nataf, Martyn Thomas, Volker Schächinger, Bernard De Bruyne, Hélène Eltchaninoff, Matthias Thielmann, Dominique Himbert, Mauro Romano, Patrick Serruys, Gerhard Wimmer-Greinecker; PARTNER EU Investigator Group
Collaborators, Affiliations
Multicenter Study

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study

Thierry Lefèvre et al. Eur Heart J. 2011 Jan.

Abstract

Background: Transcatheter aortic valve implantation (TAVI) has emerged as a new therapeutic option in high-risk patients with severe aortic stenosis.

Aims: PARTNER EU is the first study to evaluate prospectively the procedural and mid-term outcomes of transfemoral (TF) or transapical (TA) implantation of the Edwards SAPIEN® valve involving a multi-disciplinary approach.

Methods and results: Primary safety endpoints were 30 days and 6 months mortality. Primary efficacy endpoints were haemodynamic and functional improvement at 12 months. One hundred and thirty patients (61 TF, 69 TA), aged 82.1 ± 5.5 years were included. TA patients had higher logistic EuroSCORE (33.8 vs. 25.7%, P = 0.0005) and more peripheral disease (49.3 vs. 16.4%, P< 0.0001). Procedures were aborted in four TA (5.8%) and six TF cases (9.8%). Valve implantation was successful in the remaining patients in 95.4 and 96.4%, respectively. Thirty days and 6 months survival were 81.2 and 58.0% (TA) and 91.8 and 90.2% (TF). In both groups, mean aortic gradient decreased from 46.9 ± 18.1 to 10.9 ± 5.4 mmHg 6 months post-TAVI. In total, 78.1 and 84.8% of patients experienced significant improvement in New York Heart Association (NYHA) class, whereas 73.9 and 72.7% had improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in TA and TF cohorts, respectively.

Conclusion: This first team-based multi-centre European TAVI registry shows promising results in high-risk patients treated by TF or TA delivery. Survival rates differ significantly between TF and TA groups and probably reflect the higher risk profile of the TA cohort. Optimal patient screening, approach selection, and device refinement may improve outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Procedural outcome.
Figure 2
Figure 2
(A) Overall survival for transapical patients. (B) Overall survival for transfemoral patients.
Figure 3
Figure 3
Predicted 1 year mortality vs. Logistic Euroscore.
See this image and copyright information in PMC

References

    1. Charlson E, Legedza ATR, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis. 2006;15:312–321. - PubMed
    1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231–1243. doi:10.1016/S0195-668X(03)00201-X. - DOI - PubMed
    1. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg. 2006;82:2111–2115. doi:10.1016/j.athoracsur.2006.07.048. - DOI - PubMed
    1. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg. 2006;82:2116–2122. doi:10.1016/j.athoracsur.2006.07.043. - DOI - PubMed
    1. Andersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur Heart J. 1992;13:704–708. - PubMed

Publication types